High-affinity immunoglobulin E receptor-bound IgE complex (IgE-FcεRI)

The complex of allergen-specific Immunoglobulin E (IgE) bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils is the primary molecular assembly responsible for Type I hypersensitivity reactions. In sensitized individuals, IgE molecules are tethered to the cell surface via the FcεRI, which is a tetrameric receptor (αβγ2) that binds the Fc region of IgE with exceptionally high affinity (UniProt P12319). Upon subsequent exposure to an allergen, the cross-linking of these pre-bound IgE-FcεRI complexes initiates an intracellular signaling cascade involving Lyn and Syk kinases, leading to the rapid degranulation of mast cells and basophils and the release of inflammatory mediators such as histamine and leukotrienes (StatPearls, Type I Hypersensitivity). While traditional anti-IgE biologics like omalizumab function by sequestering free serum IgE to prevent its binding to FcεRI, they cannot access the IgE once it is already bound to the receptor due to steric hindrance (PubMed: 24636083). Consequently, the pre-existing IgE-FcεRI complex is a target for a new class of disruptive inhibitors, including engineered DARPins and specific monoclonal antibodies like 8D6, which are designed to actively displace IgE from the receptor to provide rapid desensitization in conditions like allergic asthma and chronic spontaneous urticaria (Gasser et al., 2020, Nature Communications; Eggel et al., 2014, JACI).

Other names

Pre-existing allergen-specific IgE bound to FcεRI on mast cells and basophilsFcεRI-bound IgESensitized mast cell IgESurface-bound IgEAllergen-specific IgE-FcεRI complex

Active dissociation of pre-bound IgE from the FcεRI receptor (disruptive mechanism) and sequestration of free IgE to prevent new complex formation.